Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Reports: Jubilant LifeSciences FY12 | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Reports: Jubilant LifeSciences FY12

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Jubilant LifeSciences

4Q Revenues: $216.2 million

4Q Loss: $11.7 million

FY Revenues: $786.7 million

FY Earnings: $2.8 million

Comments: CMO operations, including the Jubilant HollisterStier operations, were up 17% year-on-year to $114 million in FY12. The Generics unit ballooned 161% to $98 million. Specialty Pharma was up 25% to $57 million. Drug Discovery & Development was up 16% to $45 million. The API business grew 33% to $83 million. The Pharmaceuticals unit overall posted revenues of $400 million, up 41%. The Life Science Ingredients Business was up 11% to $387 million. Extraordinary charges of $64 million wiped out most earnings for the year.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics